5-[3,3-Bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in the treatment of childhood malignancy

Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):371-6.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Child
  • Clinical Trials as Topic
  • Humans
  • Imidazoles / adverse effects
  • Imidazoles / therapeutic use*
  • Leukemia, Lymphoid / drug therapy
  • Neoplasm Metastasis
  • Neoplasms / drug therapy*
  • Neuroblastoma / drug therapy
  • Nitrogen Mustard Compounds / adverse effects
  • Nitrogen Mustard Compounds / therapeutic use*
  • Osteosarcoma / drug therapy
  • Rhabdomyosarcoma / drug therapy
  • Sarcoma, Ewing / drug therapy
  • Triazenes / adverse effects
  • Triazenes / therapeutic use*

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Nitrogen Mustard Compounds
  • Triazenes